# US 2015/0105336 A1 · Mucosa-elevating agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105336 A1
- Document ID: US20150105336A1
- Status: Published application
- Kind: A1
- Application number: 14/383,801
- Filed: 2013-03-08
- Published: 2015-04-16
- Earliest claimed: 2012-03-09
- Assignees: 3-D Matrix, Ltd.
- Applicants: 3-D Matrix, Ltd.
- Inventors: Kentaro Takamura; Satoru Kobayashi; Noriaki Matsuda
- Web page: https://patentgrep.com/patent/US20150105336A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 27/22: Polypeptides or derivatives thereof {, e.g. degradation products}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61L 2430/34: for soft tissue reconstruction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a β structure in an aqueous solution at physiological pH and/or in the presence of cations.

## Claims

### Claim 1

A mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a β structure in an aqueous solution at physiological pH and/or in the presence of cations.

### Claim 2 (depends on 1)

The mucosa-elevating agent according to claim 1, wherein the peptide has a repetitive sequence of a sequence consisting of arginine, alanine, aspartic acid and alanine, a sequence consisting of isoleucine, glutamic acid, isoleucine and lysine, or a sequence consisting of lysine, leucine, aspartic acid and leucine.

### Claim 3 (depends on 1, 2)

The mucosa-elevating agent according to claim 1 or 2, wherein the peptide is consisted of the amino acid sequence described in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.

### Claim 4 (depends on 1)

The mucosa-elevating agent according to claim 1, further containing a pharmaceutical agent.

### Claim 5 (depends on 4)

The mucosa-elevating agent according to claim 4, wherein the pharmaceutical agent is a pharmaceutically acceptable pigment.

### Claim 6 (depends on 4)

The mucosa-elevating agent according to claim 4, wherein the pharmaceutical agent is
selected from the group consisting of glucose, sucrose, refined sucrose, lactose, maltose, trehalose, dextran, iodine, lysozyme chloride, dimethyl isopropylazulene, tretinoin tocoferil, iodopovidone, alprostadil alfadex, anisyl alcohol, isoamyl salicylate, α,α-dimethylphenylethyl alcohol, bacdanol, helional, silver sulfadiazine, bucladesine sodium, alprostadil alfadex, gentamycin sulfate, tetracycline hydrochloride, fusidate sodium, mupirocin calcium hydrate and isoamyl benzoate.

### Claim 7 (depends on 1)

The mucosa-elevating agent according to claim 1, which is injected between a mucous membrane and a muscle layer.

### Claim 8 (depends on 1)

The mucosa-elevating agent according to claim 1, wherein the mucous membrane is gastrointestinal mucosa.

### Claim 9 (depends on 1)

The mucosa-elevating agent according to claim 1, which is used in mucosal resection.

### Claim 10 (depends on 1)

The mucosa-elevating agent according to claim 1, which is used in submucosal layer dissection.

### Claim 11 (depends on 1)

The mucosa-elevating agent according to claim 1, which can be additionally injected.

### Claim 12 (depends on 1)

The mucosa-elevating agent according to claim 1, which is in a form of being filled in a syringe.

### Claim 13 (depends on 1)

The mucosa-elevating agent according to claim 1, which has a wound-healing effect.

### Claim 14 (depends on 1)

The mucosa-elevating agent according to claim 1, which has a scar-preventing effect or constriction-preventing effect.

### Claim 15 (depends on 1)

The mucosa-elevating agent according to claim 1, which has a hemostatic effect.

### Claim 16 (depends on 1)

The mucosa-elevating agent according to claim 1, which is in a liquid form that gels in the body.
